150 related articles for article (PubMed ID: 15842254)
1. Cellular quiescence induced by contact inhibition or serum withdrawal in C3H10T1/2 cells.
Gos M; Miloszewska J; Swoboda P; Trembacz H; Skierski J; Janik P
Cell Prolif; 2005 Apr; 38(2):107-16. PubMed ID: 15842254
[TBL] [Abstract][Full Text] [Related]
2. The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal.
Pause A; Lee S; Lonergan KM; Klausner RD
Proc Natl Acad Sci U S A; 1998 Feb; 95(3):993-8. PubMed ID: 9448273
[TBL] [Abstract][Full Text] [Related]
3. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
4. The von Hippel-Lindau tumor suppressor gene protects cells from UV-mediated apoptosis.
Schoenfeld AR; Parris T; Eisenberger A; Davidowitz EJ; De Leon M; Talasazan F; Devarajan P; Burk RD
Oncogene; 2000 Nov; 19(51):5851-7. PubMed ID: 11127815
[TBL] [Abstract][Full Text] [Related]
5. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling.
Wykoff CC; Pugh CW; Maxwell PH; Harris AL; Ratcliffe PJ
Oncogene; 2000 Dec; 19(54):6297-305. PubMed ID: 11175344
[TBL] [Abstract][Full Text] [Related]
6. The transcriptional programme of contact-inhibition.
Küppers M; Ittrich C; Faust D; Dietrich C
J Cell Biochem; 2010 Aug; 110(5):1234-43. PubMed ID: 20564218
[TBL] [Abstract][Full Text] [Related]
7. Decreased growth of Vhl-/- fibrosarcomas is associated with elevated levels of cyclin kinase inhibitors p21 and p27.
Mack FA; Patel JH; Biju MP; Haase VH; Simon MC
Mol Cell Biol; 2005 Jun; 25(11):4565-78. PubMed ID: 15899860
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of mitotic inhibition in corneal endothelium: contact inhibition and TGF-beta2.
Joyce NC; Harris DL; Mello DM
Invest Ophthalmol Vis Sci; 2002 Jul; 43(7):2152-9. PubMed ID: 12091410
[TBL] [Abstract][Full Text] [Related]
9. von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids.
Lieubeau-Teillet B; Rak J; Jothy S; Iliopoulos O; Kaelin W; Kerbel RS
Cancer Res; 1998 Nov; 58(21):4957-62. PubMed ID: 9810005
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of Cap43 gene by von Hippel-Lindau tumor suppressor protein in human renal cancer cells.
Masuda K; Ono M; Okamoto M; Morikawa W; Otsubo M; Migita T; Tsuneyoshi M; Okuda H; Shuin T; Naito S; Kuwano M
Int J Cancer; 2003 Jul; 105(6):803-10. PubMed ID: 12767066
[TBL] [Abstract][Full Text] [Related]
11. Control of density-dependent, cell state-specific signal transduction by the cell adhesion molecule CEACAM1, and its influence on cell cycle regulation.
Scheffrahn I; Singer BB; Sigmundsson K; Lucka L; Obrink B
Exp Cell Res; 2005 Jul; 307(2):427-35. PubMed ID: 15950623
[TBL] [Abstract][Full Text] [Related]
12. Tumor suppressor protein VHL is induced at high cell density and mediates contact inhibition of cell growth.
Baba M; Hirai S; Kawakami S; Kishida T; Sakai N; Kaneko S; Yao M; Shuin T; Kubota Y; Hosaka M; Ohno S
Oncogene; 2001 May; 20(22):2727-36. PubMed ID: 11420685
[TBL] [Abstract][Full Text] [Related]
13. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor.
Baba M; Hirai S; Yamada-Okabe H; Hamada K; Tabuchi H; Kobayashi K; Kondo K; Yoshida M; Yamashita A; Kishida T; Nakaigawa N; Nagashima Y; Kubota Y; Yao M; Ohno S
Oncogene; 2003 May; 22(18):2728-38. PubMed ID: 12743597
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations.
Rathmell WK; Hickey MM; Bezman NA; Chmielecki CA; Carraway NC; Simon MC
Cancer Res; 2004 Dec; 64(23):8595-603. PubMed ID: 15574766
[TBL] [Abstract][Full Text] [Related]
15. Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor suppressor gene product is determined by cell density.
Lee S; Chen DY; Humphrey JS; Gnarra JR; Linehan WM; Klausner RD
Proc Natl Acad Sci U S A; 1996 Mar; 93(5):1770-5. PubMed ID: 8700833
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of ocular angiogenesis by an adenovirus carrying the human von Hippel-Lindau tumor-suppressor gene in vivo.
Akiyama H; Tanaka T; Itakura H; Kanai H; Maeno T; Doi H; Yamazaki M; Takahashi K; Kimura Y; Kishi S; Kurabayashi M
Invest Ophthalmol Vis Sci; 2004 May; 45(5):1289-96. PubMed ID: 15111579
[TBL] [Abstract][Full Text] [Related]
17. Renal cell carcinoma- and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones.
Tsuchiya MI; Okuda H; Takaki Y; Baba M; Hirai S; Ohno S; Shuin T
Oncol Rep; 2005 Jun; 13(6):1033-41. PubMed ID: 15870918
[TBL] [Abstract][Full Text] [Related]
18. Identification of novel VHL target genes and relationship to hypoxic response pathways.
Maina EN; Morris MR; Zatyka M; Raval RR; Banks RE; Richards FM; Johnson CM; Maher ER
Oncogene; 2005 Jun; 24(28):4549-58. PubMed ID: 15824735
[TBL] [Abstract][Full Text] [Related]
19. The effect of von hippel-lindau gene transfer on human vascular smooth muscle cell proliferation and apoptosis.
Jacob T; Ascher E; Hingorani A; Kallakuri S
Vasc Endovascular Surg; 2005; 39(1):25-32. PubMed ID: 15696245
[TBL] [Abstract][Full Text] [Related]
20. Requirement for the von Hippel-Lindau tumor suppressor gene for functional epidermal growth factor receptor blockade by monoclonal antibody C225 in renal cell carcinoma.
Perera AD; Kleymenova EV; Walker CL
Clin Cancer Res; 2000 Apr; 6(4):1518-23. PubMed ID: 10778984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
